Cetirizine,
does it really help with Suppression of wheals and itch in chronic spontaneous urticaria?
research showsCetirizine 10 mg is rated C. Complete suppression was pooled from Pfizer-funded Breneman 1995 and UCB-funded Go 1989; both were short, and one had 27.3% attrition. The pooled result was 32 of 88 versus 12 of 90, RR 2.72 (95% CI 1.51 to 4.91).
ads claimFamiliar rhinitis efficacy should not be expanded to every urticaria syndrome or high-dose escalation. This verdict is restricted to standard-dose treatment of chronic spontaneous urticaria.
Useful facts when choosing a product
- The key trial used a four-point assessment of wheals, episodes, and itch rather than ISS7.
- Verdict 851 concerns allergic rhinitis and its evidence was not transferred.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.cetirizine.UNK.suppression-of-wheals-and-itch-in-chronic-spontaneous-urticaria.assess.MULTIUnknown > Cetirizine > Unknown > Suppression of wheals and itch in chronic spontaneous urticaria > Association or change assessment > Multiple: primary unresolved
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Whether cetirizine 10 mg suppresses chronic spontaneous urticaria. Complete suppression was pooled from Breneman 1995 and Go 1989, two trials with 178 participants: 32 of 88 versus 12 of 90, RR 2.72 (95% CI 1.51 to 4.91), with no heterogeneity. Go 1989 included 56 participants and gave RR 2.80 (1.17 to 6.73). Breneman 1995 was funded by Pfizer and Go 1989 by UCB. Competing manufacturers are not public or nonprofit independent funding, so I0 remains. An independent Cochrane review exists, but it synthesized manufacturer-funded trials; no decisive independently funded trial was identified. No modern ISS7 MCID is claimed. verdict 851, which is B with 72 points, concerns allergic rhinitis and was not transferred. verdict 1674, which is C with 58 points, and verdict 646, which is B with 69 points, concern other indications.
Why this is classified as C (50)
P, R1, I0, E+, and B2 derive C with 50 points because the trials belong to one manufacturer program and have at least two avoidable limitations.
Counterpoint. Dose escalation and biologic treatment after standard-dose failure are separate evidence questions.
Rejudgment record. Cross-check applied — Patient-centered symptom efficacy replicated at standard dose, but decisive evidence was manufacturer-funded only and limited by short duration and high attrition
| Endpoint | P | Symptom or function itself is the target - including patient reports and performance tests |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduction of wheals and itch at the standard dose | C | Positive versus placebo but based on short manufacturer-funded trials. |
| Complete suppression of urticaria | C | Two trials produced pooled RR 2.72. |
| Symptom control over four weeks | C | Long-term persistence was not directly established. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Breneman DL. 1996 | Four-week randomized double-blind double-dummy placebo- and active-controlled trial | 188 randomized; nine withdrew, about 179 analyzed | Manufacturer funding from Pfizer Laboratories | Four-point efficacy assessment of wheals, episodes, and itch | Cetirizine was superior from day one, P=0.002; primary symptom endpoint succeeded | Direct standard-dose randomized trial |
| Sharma M et al. 2014 | Cochrane systematic review and meta-analysis | Two cetirizine complete-suppression trials; 178 analyzed | Academic Cochrane review; Breneman 1995 was funded by Pfizer and Go 1989 by UCB | Complete suppression of urticaria | 32 of 88 versus 12 of 90, RR 2.72 (95% CI 1.51 to 4.91), I-squared zero | Replication and bias assessment |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-24).
Final verification and publication gate: Codex · Evidence date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Cetirizine x suppression of chronic spontaneous urticaria — Evidence Grade C·50. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/cetirizine-chronic-spontaneous-urticaria-standard-dose/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.